

103. . The nucleic acid molecule of claim 102, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 150-1928 of SEQ ID NO:1.

104. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:5.

105. The nucleic acid molecule of claim 104, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 267-1928 of SEQ ID NO:1.

106. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:6.

107. The nucleic acid molecule of claim 106, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 291-1928 of SEQ ID NO:1.

108. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:8.

109. The nucleic acid molecule of claim 108, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 180-1949 of SEQ ID NO:2.

110. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:9.

111. The nucleic acid molecule of claim 110, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 270-1949 of SEQ ID NO:2.

112. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:21.

113. The nucleic acid molecule of claim 112, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 1-1881 of SEQ ID NO:20.

114. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:25.

115. The nucleic acid molecule of claim 114, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 1-2010 of SEQ ID NO:24.

116. The nucleic acid molecule of claim 98, wherein said nucleic acid encodes a human sel-10 polypeptide comprising the amino acid sequence of SEQ ID NO:27.

117. The nucleic acid molecule of claim 116, wherein said nucleic acid molecule comprises the nucleotide sequence of residues 1-2001 of SEQ ID NO:26.

118. A vector comprising the isolated nucleic acid molecule of claim 98.

119. The vector of claim 118 wherein the nucleic acid molecule is operably linked to a promoter for the expression of a sel-10 polypeptide.

120 A host cell comprising the vector of claim 119.

121. The host cell of claim 120, wherein said host is a eukaryotic host.


122. A method of obtaining a sel-10 polypeptide comprising culturing the host cell of claim 120 and isolating said sel-10 polypeptide.

For the examiner's convenience the currently pending claims are reproduced on a separate sheet.

The cancellation and substitution of additional claims is merely intended to expedite prosecution, to emphasize the considerable degree of sequence similarity between the polypeptides of the invention and to mirror the claim format of related application 09/328,877. The claims although having different dependencies are substantial duplicates of claims the Examiner has previously indicated are allowable. No subject matter is intended to be surrendered.

Applicant has also attached a sequence alignment of the polypeptides and polynucleotides of the invention (designated "Exhibit A") for the Examiner's convenience so that she may appreciate the considerable sequence similarity of the sequences of the invention. For the purposes of restriction practice it is intended that claim 43 be considered a linking or genus claim.

Respectfully submitted,



Edward F. Rehberg, Attorney
Registration No. 34,703

Date: 4-24-02

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001